Glenmark Pharmaceuticals has signed an exclusive licensing agreement with Helsinn Group to roll out Akynzeo in India and Nepal.

Developed by Helsinn, Akynzeo is a fixed dose combination of 300mg netupitant and 0.5mg palonosetron formulated as capsules for oral administration. It is approved to treat chemotherapy-induced nausea and vomiting (CINV).

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Said to be Helsinn’s first deal of this kind in India, the agreement gives Glenmark exclusive marketing rights for the drug in India and Nepal.

Helsinn Group chief commercial officer Andrea Meoli said: “We are excited to begin our first collaboration agreement in India with our new partner Glenmark Pharmaceuticals.

“Glenmark’s renowned expertise in sales, marketing and distribution in this region will mean that Akynzeo, a key anti-emetic product, will be made available to more patients suffering from the side effects of cancer treatment in the important markets of India and Nepal.”

“Akynzeo will help Indian patients undergoing chemotherapy and struggling to manage CINV to address this issue in a much better manner.”

Akynzeo is already available in multiple markets, including the US and EU.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The safety of the drug was assessed in three double blind, active-controlled clinical trials involving 1169 subjects undergoing a minimum of one highly or moderately emetogenic chemotherapy cycle for cancer.

It achieved 90% complete response rates over five days in patients treated with HEC cisplatin-based chemotherapy, compared with 77% in oral palonosetron.

Glenmark India Formulations Middle East and Africa president Sujesh Vasudevan said: “We are happy to partner with Helsinn, a leader in cancer supportive care. Akynzeo will help Indian patients undergoing chemotherapy and struggling to manage CINV to address this issue in a much better manner.

“I am sure the launch of Akynzeo will fortify our presence in oncology, which is a key therapeutic focus area for the company.”